Dermata Therapeutics Inc
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept… Read more
Market Cap & Net Worth: Dermata Therapeutics Inc (DRMA)
Dermata Therapeutics Inc (NASDAQ:DRMA) has a market capitalization of $3.90 Million ($3.90 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #36745 globally and #11954 in its home market, demonstrating a -8.27% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dermata Therapeutics Inc's stock price $1.22 by its total outstanding shares 3197860 (3.20 Million).
Dermata Therapeutics Inc Market Cap History: 2021 to 2026
Dermata Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows change from $1.34 Billion to $3.90 Million (-77.86% CAGR).
Index Memberships
Dermata Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #907 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2828 of 3165 |
Weight: Dermata Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Dermata Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dermata Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of DRMA by Market Capitalization
Companies near Dermata Therapeutics Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Dermata Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Dermata Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Dermata Therapeutics Inc's market cap moved from $1.34 Billion to $ 3.90 Million, with a yearly change of -77.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.90 Million | -47.41% |
| 2025 | $7.42 Million | +71.85% |
| 2024 | $4.32 Million | -85.25% |
| 2023 | $29.26 Million | -90.68% |
| 2022 | $313.90 Million | -76.49% |
| 2021 | $1.34 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Dermata Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.90 Million USD |
| MoneyControl | $3.90 Million USD |
| MarketWatch | $3.90 Million USD |
| marketcap.company | $3.90 Million USD |
| Reuters | $3.90 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.